ABIVAX Société Anonyme (AAVXF)
USD 11.05
(0.0%)
USD 11.05
(0.0%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 44.69 Million EUR | 22.21% |
| 2022 | 36.57 Million EUR | -31.57% |
| 2021 | 53.44 Million EUR | 87.89% |
| 2020 | 28.44 Million EUR | 37.13% |
| 2019 | 20.74 Million EUR | 90.3% |
| 2018 | 10.9 Million EUR | 4060.31% |
| 2017 | 262 Thousand EUR | -17.09% |
| 2016 | 316 Thousand EUR | 271.76% |
| 2015 | 85 Thousand EUR | -95.93% |
| 2014 | 2.08 Million EUR | -9.95% |
| 2013 | 2.32 Million EUR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 73.57 Million EUR | 0.0% |
| 2024 Q1 | 73.57 Million EUR | 64.61% |
| 2023 FY | 44.69 Million EUR | 22.21% |
| 2023 Q3 | 60.34 Million EUR | 141.09% |
| 2023 Q1 | 28.8 Million EUR | -21.25% |
| 2023 Q4 | 44.69 Million EUR | -25.94% |
| 2023 Q2 | 25.03 Million EUR | -13.09% |
| 2022 Q1 | 47.6 Million EUR | -10.93% |
| 2022 Q4 | 36.57 Million EUR | 4.48% |
| 2022 Q3 | 35 Million EUR | -28.33% |
| 2022 Q2 | 48.84 Million EUR | 2.6% |
| 2022 FY | 36.57 Million EUR | -31.57% |
| 2021 Q2 | 5 Million EUR | -79.03% |
| 2021 Q3 | 40.3 Million EUR | 706.16% |
| 2021 Q4 | 53.44 Million EUR | 32.59% |
| 2021 FY | 53.44 Million EUR | 87.89% |
| 2021 Q1 | 23.84 Million EUR | -16.18% |
| 2020 Q1 | 20.19 Million EUR | -2.63% |
| 2020 Q2 | 20.19 Million EUR | 0.0% |
| 2020 Q3 | 33.98 Million EUR | 68.24% |
| 2020 Q4 | 28.44 Million EUR | -16.29% |
| 2020 FY | 28.44 Million EUR | 37.13% |
| 2019 Q4 | 20.74 Million EUR | 0.0% |
| 2019 Q1 | 19.48 Million EUR | 78.72% |
| 2019 Q3 | 20.74 Million EUR | 418.58% |
| 2019 FY | 20.74 Million EUR | 90.3% |
| 2019 Q2 | 4 Million EUR | -79.47% |
| 2018 Q3 | 10.9 Million EUR | 0.0% |
| 2018 FY | 10.9 Million EUR | 4060.31% |
| 2018 Q2 | - EUR | 0.0% |
| 2018 Q1 | - EUR | -100.0% |
| 2018 Q4 | 10.9 Million EUR | 0.0% |
| 2017 Q4 | 262 Thousand EUR | 0.0% |
| 2017 Q3 | - EUR | -100.0% |
| 2017 Q2 | 331 Thousand EUR | 335.53% |
| 2017 Q1 | 76 Thousand EUR | -75.95% |
| 2017 FY | 262 Thousand EUR | -17.09% |
| 2016 Q2 | 386 Thousand EUR | 739.13% |
| 2016 Q4 | 316 Thousand EUR | 0.0% |
| 2016 Q3 | 316 Thousand EUR | -18.13% |
| 2016 Q1 | 46 Thousand EUR | -45.88% |
| 2016 FY | 316 Thousand EUR | 271.76% |
| 2015 FY | 85 Thousand EUR | -95.93% |
| 2015 Q3 | 435 Thousand EUR | 70.59% |
| 2015 Q4 | 85 Thousand EUR | -80.46% |
| 2015 Q1 | 255 Thousand EUR | -87.8% |
| 2015 Q2 | 255 Thousand EUR | 0.0% |
| 2014 Q4 | 2.08 Million EUR | 0.02% |
| 2014 Q3 | 2.08 Million EUR | 0.0% |
| 2014 Q1 | - EUR | 0.0% |
| 2014 FY | 2.08 Million EUR | -9.95% |
| 2013 FY | 2.32 Million EUR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | - USD | -Infinity% |
| Nanobac Pharmaceuticals, Incorporated | - USD | -Infinity% |
| SQZ Biotechnologies Company | 20.9 Million USD | -113.769% |
| Evofem Biosciences, Inc. | 8000.00 USD | -558612.5% |
| Santhera Pharmaceuticals Holding AG | 1.75 Million USD | -2446.143% |
| Mesoblast Limited | 100.29 Million USD | 55.434% |
| Propanc Biopharma, Inc. | 58.64 Thousand USD | -76120.115% |
| Genus plc | 228.2 Million USD | 80.413% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| CNBX Pharmaceuticals Inc. | - USD | -Infinity% |
| Marizyme, Inc. | 667.12 Thousand USD | -6599.904% |
| ContraFect Corporation | 2.21 Million USD | -1922.489% |
| Nymox Pharmaceutical Corporation | - USD | -Infinity% |
| PsyBio Therapeutics Corp. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.4 Million USD | -3085.966% |
| Intellipharmaceutics International Inc. | - USD | -Infinity% |
| AXIM Biotechnologies, Inc. | 5.42 Million USD | -723.683% |
| MultiCell Technologies, Inc. | 36.43 USD | -122692735.575% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 55.61 Million USD | 19.627% |
| EV Biologics, Inc. | - USD | -Infinity% |
| Q BioMed Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 2.22 Million USD | -1907.951% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -3538.751% |
| Biomind Labs Inc. | - USD | -Infinity% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 166.1 Million USD | 73.091% |
| Oncotelic Therapeutics, Inc. | 1.89 Million USD | -2254.372% |
| Skye Bioscience, Inc. | 171.23 Thousand USD | -26003.487% |
| Therapeutic Solutions International, Inc. | 5512.00 USD | -810803.483% |
| THC Farmaceuticals, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | - USD | -Infinity% |
| IMV Inc. | 27.39 Million USD | -63.136% |
| Acro Biomedical Co., Ltd. | - USD | -Infinity% |
| Curative Biotechnology, Inc. | - USD | -Infinity% |
| GB Sciences, Inc. | 322 Thousand USD | -13781.056% |
| Alpha Cognition Inc. | - USD | -Infinity% |
| HST Global, Inc. | - USD | -Infinity% |
| CSL Limited | 11.23 Billion USD | 99.602% |
| Halberd Corporation | 150 Thousand USD | -29698.0% |
| Enzolytics Inc. | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| Affymax, Inc. | - USD | -Infinity% |
| SYBLEU INC | 300 Thousand USD | -14799.0% |
| Nuo Therapeutics, Inc. | 164.2 Thousand USD | -27120.243% |
| argenx SE | 15.35 Million USD | -191.11% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 20.31 Million USD | -120.052% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 4456.00 USD | -1002974.506% |
| Genscript Biotech Corporation | 287.12 Million USD | 84.433% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 126.3 Thousand USD | -35288.988% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -19393.569% |
| American Oriental Bioengineering, Inc. | 554.59 Thousand USD | -7959.467% |
| Provectus Biopharmaceuticals, Inc. | 25.29 Thousand USD | -176574.967% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 8.26 Million USD | -440.864% |
| Cotinga Pharmaceuticals Inc. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 265.63 Thousand USD | -16726.472% |
| ONE Bio Corp. | 592.19 Thousand USD | -7447.645% |
| Reve Technologies, Inc. | 1064.00 USD | -4200745.865% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Agentix Corp. | - USD | -Infinity% |
| LadRx Corporation | - USD | -Infinity% |
| Cell Source, Inc. | - USD | -Infinity% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 149.61 Thousand USD | -29774.878% |
| Regen BioPharma, Inc. | 149.61 Thousand USD | -29774.878% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | - USD | -Infinity% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Kadimastem Ltd | 229.69 Thousand USD | -19359.622% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| CytoDyn Inc. | 141 Thousand USD | -31600.0% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 80 Thousand USD | -55771.25% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | -471.576% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | - USD | -Infinity% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 369.04 Thousand USD | -12011.4% |
| International Stem Cell Corporation | 445 Thousand USD | -9944.27% |
| Bioxytran, Inc. | - USD | -Infinity% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.15 Million USD | -448.429% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | 457 Thousand USD | -9680.525% |
| Neutra Corp. | - USD | -Infinity% |
| Windtree Therapeutics, Inc. | 1.16 Million USD | -3749.871% |
| PureTech Health plc | 18.25 Million USD | -144.915% |
| Coeptis Therapeutics, Inc. | 150 Thousand USD | -29698.0% |
| IXICO plc | 275 Thousand USD | -16153.455% |
| IntelGenx Technologies Corp. | 11.83 Million USD | -277.54% |
| Gelesis Holdings, Inc. | 26.3 Million USD | -69.892% |
| CSL Limited | 11.23 Billion USD | 99.602% |
| Cellectis S.A. | 36.21 Million USD | -23.434% |